U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H25N.CH4O3S
Molecular Weight 387.536
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MELITRACEN METHANESULFONATE

SMILES

CS(O)(=O)=O.CN(C)CCC=C1C2=C(C=CC=C2)C(C)(C)C3=C1C=CC=C3

InChI

InChIKey=LXKCTBYAJVUILB-UHFFFAOYSA-N
InChI=1S/C21H25N.CH4O3S/c1-21(2)19-13-7-5-10-17(19)16(12-9-15-22(3)4)18-11-6-8-14-20(18)21;1-5(2,3)4/h5-8,10-14H,9,15H2,1-4H3;1H3,(H,2,3,4)

HIDE SMILES / InChI
Molecular Formula C21H25N
Molecular Weight 291.4299
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.aci-bd.com/Brand/Adelax.pdf and https://www.ncbi.nlm.nih.gov/pubmed/18331614

Melitracen (HCl) is a tricyclic antidepressant with actions and effects similar to amitriptyline.Melitracen (HCl) is given orally in the treatment of depression. It should be withdrawn gradually to reduce the risk of withdrawl symptoms. Melitracen (HCl) is primarily indicated in conditions like Anxiety, Asthenia, Depression, gastro-intestinal disorders associated with anxiety and agitation. Melitracen is marketed in Europe and Japan by Lundbeck and Takeda, respectively, for the treatment of depression and anxiety. In addition to single drug preparations, it is also available as Deanxit, a combination product containing both melitracen and flupentixol. The way this drug works hasn’t been thoroughly researched, but some hypothesize that it may work similarly to the drugs Imipramine and Amitriptyline. In comparison to older TCAs, this drug is thought to work more quickly with more favorable side effects.

CNS Activity

CNS Active
3913
Curator's Comment: Melitracen acts in the brain

Originator

Kefalas
3
Curator's Comment: Melitracen was patented in 1963 by Kefalas A/S

Approval Year

Unknown
139594
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Deanxit

Approved Use

Anxiety − Depression − Asthenia. Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts.

Launch Date

8.8361278E11
Primary
Approved
8429
Deanxit

Approved Use

Anxiety − Depression − Asthenia. Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts.

Launch Date

8.8361278E11
Primary
Approved
8429
Deanxit

Approved Use

Anxiety − Depression − Asthenia. Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts.

Launch Date

8.8361278E11
PubMed

PubMed

TitleDatePubMed
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.
2005 Dec 9
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.
2009 Nov
[Study on catgut implantation therapy compared with Deanxit for treatment of depression].
2010 Aug
Patents

Patents

CN100560064C
3
CN103877088A
3
CN104288153A
3
EP2374450 A1
3

Sample Use Guides

In Vivo Use Guide
Oral Depression Adult: Initially, 25 mg bid-tid, gradually increased to 225 mg daily if necessary. Elderly: Initially, 25 mg daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:20:16 UTC 2023
Edited
by admin
on Sat Dec 16 08:20:16 UTC 2023
Record UNII
HS8YY1BM7I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MELITRACEN METHANESULFONATE
Common Name English
.DELTA.9(10H),.GAMMA.-ANTHRACENEPROPYLAMINE, N,N,10,10-TETRAMETHYL-, METHANESULFONATE
Common Name English
MELITRACEN MESYLATE
Common Name English
1-PROPANAMINE, 3-(10,10-DIMETHYL-9(10H)-ANTHRACENYLIDENE)-N,N-DIMETHYL-, METHANESULFONATE (1:1)
Systematic Name English
1-PROPANAMINE, 3-(10,10-DIMETHYL-9(10H)-ANTHRACENYLIDENE)-N,N-DIMETHYL-, METHANESULFONATE
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID40185082
Created by admin on Sat Dec 16 08:20:17 UTC 2023 , Edited by admin on Sat Dec 16 08:20:17 UTC 2023
PRIMARY
CAS
31149-47-0
Created by admin on Sat Dec 16 08:20:17 UTC 2023 , Edited by admin on Sat Dec 16 08:20:17 UTC 2023
PRIMARY
PUBCHEM
53447046
Created by admin on Sat Dec 16 08:20:17 UTC 2023 , Edited by admin on Sat Dec 16 08:20:17 UTC 2023
PRIMARY
FDA UNII
HS8YY1BM7I
Created by admin on Sat Dec 16 08:20:17 UTC 2023 , Edited by admin on Sat Dec 16 08:20:17 UTC 2023
PRIMARY
Related Record Type Details
Structure of MELITRACEN
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of MELITRACEN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966